Table 2. Clinical parameters at enrollment related to primary outcome of intention to treatment.
| Increased aldosterone secretion | Decreased aldosterone secretion | p | |
|---|---|---|---|
| Patients (n) | 19 | 10 | |
| Demography | |||
| Sex (M) | 10 (52.6) | 2 (20.0) | 0.126 |
| Age (y/o) | 49.7± 11.0 | 49.1 ± 9.5 | 0.862 |
| Charlson comorbidity index | 0.37 ± 0.6 | 0.1 ± 0.32 | 0.125 |
| MAP (mmHg) | 115.1 ± 11.7 | 116.2 ± 10.0 | 0.798 |
| Latency of HTN (yr) | 9.7± 8.1 | 10.1 ± 6.0 | 0.885 |
| BMI (kg/m2) | 26.5 ± 3.9 | 24.5 ± 2.8 | 0.176 |
| Aldosteronism profile | |||
| APA | 11 (57.9) | 4 (40) | 0.450 |
| Potassium (mmole/L) | 3.7 ± 0.7 | 3.6± 0.5 | 0.553 |
| PRA (ng/mL/hr) | 0.76 ± 0.74 | 0.67 ± 1.00 | 0.809 |
| PAC (ng/dL) # | 44.0(38.9-55.2) | 56.9(42.7-82.1) | 0.347 |
| Log [ARR] | 1.89 ± 0.49 | 2.45± 0.97 | 0.097 |
| Urine ald /creatinine | 2.36 ± 2.65 | 3.57 ± 2.50 | 0.247 |
| Urine K /creatinine | 0.41± 0.23 | 0.52± 0.17 | 0.178 |
| Metabolic profile | |||
| Cholesterol (mg/dl) | 205.2± 45.3 | 195.6 ± 20.8 | 0.442 |
| Triglyceride (mg/dl) | 183.3 ± 135.1 | 164 ± 145.2 | 0.732 |
| HDL (mg/dl) | 44.1± 10.2 | 42.8 ± 6.8 | 0.809 |
| Uric Acid | 6.8 ± 1.3 | 6.47 ± 1.9 | 0.673 |
| FPG (mg/dL) | 93.56 ± 12.0 | 102.9 ± 15.5 | 0.149 |
| HOMA-IR (mU/L·mmol/L) | 36.5 ± 20.7 | 45.3 ± 27.0 | 0.387 |
| Categories of hypertensive drugs before recruitment | |||
| α- blockers | 2 (20.0) | 3 (15.8) | 0.999 |
| β- blockers | 2 (20.0) | 2 (10.5) | 0.592 |
| Calcium channel blockers | 6 (60.0) | 12(63.2) | 0.999 |
| ACEI/ ARB | 3 (30.0) | 2 (10.5) | 0.306 |
| High MCP | 6 (31.6) | 9 (90) | 0.004 |
| Tumor size | 1.0 ± 0.3(11 APA patients) | 1.2 ± 0.1(4 APA patients) | 0.370 |
ACEI, angiotensin-converting enzyme inhibitors; ald, aldosterone; APA, aldosterone producing adenoma; ARB, angiotensin II receptor blockers; ARR, aldosterone-renin ratio (ng/dL per ng/mL/h); BMI, body mass index; FPG, fasting plasma glucose; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment for insulin resistance; HTN, hypertension; K, potassium; MAP, mean arterial blood pressure; MCP, metoclopramide; PAC, plasma aldosterone concentration; PRA, plasma renin activity;
Patients were withdrawn from antihypertensive medications at least 21 days before the study, with the exception of calcium antagonist or alpha-blockers.
Data were provided as the mean values ± standard deviation, Significance was determined by Wilcoxon signed rank test in nonparametric distribution.
# Median (interquartile range)
The body- mass index is the weight in kilograms divided by the square of the height in meters
To convert potassium in mmol/L to mEq/L, multiple by 1; BUN in mg/dL to mmol/L, multiple by 0.375; eGFR in mL/min to mL/s, multiple by 0.01667; PAC in ng/dL to nmol/L, multiple by 0.02774; PRA in ng/mL/hr to ng/(Lxs), multiple by 0.2778.